TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
35.24
+4.09 (13.16%)
Nov 21, 2024, 2:29 PM EST - Market open
TG Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 195.82 | 92.93 | 102.3 | 298.89 | 553.44 | 112.64 | Upgrade
|
| Short-Term Investments | 145.22 | 124.58 | 59.37 | 15.88 | 51.99 | 27.8 | Upgrade
|
| Cash & Short-Term Investments | 341.04 | 217.51 | 161.68 | 314.76 | 605.43 | 140.44 | Upgrade
|
| Cash Growth | 48.82% | 34.53% | -48.64% | -48.01% | 331.11% | 103.82% | Upgrade
|
| Accounts Receivable | 115.73 | 51.09 | - | 1.39 | - | - | Upgrade
|
| Receivables | 115.73 | 51.09 | - | 1.39 | - | - | Upgrade
|
| Inventory | 84.67 | 39.82 | - | - | - | - | Upgrade
|
| Other Current Assets | 32.63 | 9.52 | 6.6 | 14.81 | 6.31 | 8.72 | Upgrade
|
| Total Current Assets | 574.07 | 317.94 | 168.27 | 330.97 | 611.74 | 149.15 | Upgrade
|
| Property, Plant & Equipment | 7.41 | 8.15 | 9.2 | 9.23 | 9.79 | 9.68 | Upgrade
|
| Long-Term Investments | 1.13 | - | 12.4 | 35.53 | - | - | Upgrade
|
| Goodwill | - | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | Upgrade
|
| Long-Term Deferred Charges | - | 1.42 | 1.63 | 1.84 | 2.05 | 2.13 | Upgrade
|
| Other Long-Term Assets | 3.41 | 1.29 | 1.27 | 1.26 | 1.26 | 1.25 | Upgrade
|
| Total Assets | 586.01 | 329.59 | 193.57 | 379.63 | 625.64 | 163.01 | Upgrade
|
| Accounts Payable | 101.38 | 29.27 | 42.02 | 50.89 | 37.01 | 30.04 | Upgrade
|
| Accrued Expenses | 10.09 | 12.17 | 8.43 | 10.17 | 8.46 | 3.8 | Upgrade
|
| Current Portion of Long-Term Debt | 0.51 | 0.36 | 0.24 | 1.34 | 23.12 | 0.19 | Upgrade
|
| Current Portion of Leases | 1.23 | 1.45 | 1.58 | 1.44 | 1.67 | 1.62 | Upgrade
|
| Current Unearned Revenue | 9.09 | - | - | 0.2 | 0.2 | 0.15 | Upgrade
|
| Other Current Liabilities | 2.81 | 10.47 | 0.93 | 1.35 | 17.1 | 48.65 | Upgrade
|
| Total Current Liabilities | 125.11 | 53.72 | 53.2 | 65.38 | 87.55 | 84.45 | Upgrade
|
| Long-Term Debt | 244.16 | 100.12 | 71.14 | 66.79 | 7.72 | 28.97 | Upgrade
|
| Long-Term Leases | 8.42 | 9.23 | 10.34 | 9.85 | 10.41 | 10.22 | Upgrade
|
| Long-Term Unearned Revenue | 16.17 | 6.02 | 0.31 | 0.46 | 0.61 | 0.76 | Upgrade
|
| Total Liabilities | 393.86 | 169.09 | 134.99 | 142.48 | 106.29 | 124.4 | Upgrade
|
| Common Stock | 0.16 | 0.15 | 0.15 | 0.14 | 0.14 | 0.11 | Upgrade
|
| Additional Paid-In Capital | 1,747 | 1,675 | 1,586 | 1,566 | 1,500 | 739.96 | Upgrade
|
| Retained Earnings | -1,553 | -1,514 | -1,527 | -1,329 | -980.6 | -701.22 | Upgrade
|
| Treasury Stock | -2.38 | -0.23 | -0.23 | -0.23 | -0.23 | -0.23 | Upgrade
|
| Shareholders' Equity | 192.16 | 160.5 | 58.59 | 237.15 | 519.35 | 38.62 | Upgrade
|
| Total Liabilities & Equity | 586.01 | 329.59 | 193.57 | 379.63 | 625.64 | 163.01 | Upgrade
|
| Total Debt | 254.32 | 111.15 | 83.3 | 79.41 | 42.91 | 40.99 | Upgrade
|
| Net Cash (Debt) | 86.73 | 106.36 | 78.38 | 235.36 | 562.51 | 99.44 | Upgrade
|
| Net Cash Growth | -27.17% | 35.70% | -66.70% | -58.16% | 465.67% | 44.46% | Upgrade
|
| Net Cash Per Share | 0.60 | 0.72 | 0.58 | 1.78 | 4.88 | 1.13 | Upgrade
|
| Filing Date Shares Outstanding | 143.52 | 144.78 | 137.63 | 130.79 | 129.8 | 102.31 | Upgrade
|
| Total Common Shares Outstanding | 143.63 | 141.79 | 137.65 | 131.22 | 129.79 | 102.29 | Upgrade
|
| Working Capital | 448.96 | 264.22 | 115.07 | 265.58 | 524.19 | 64.7 | Upgrade
|
| Book Value Per Share | 1.34 | 1.13 | 0.43 | 1.81 | 4.00 | 0.38 | Upgrade
|
| Tangible Book Value | 192.16 | 159.7 | 57.79 | 236.35 | 518.55 | 37.82 | Upgrade
|
| Tangible Book Value Per Share | 1.34 | 1.13 | 0.42 | 1.80 | 4.00 | 0.37 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.